• 1
    Jensen OM, Esteve J, Moller H et al. Cancer in the European Community and its member states. Eur J Cancer 1990;26 1167 256
  • 2
    Boring CC, Squires TS, Tong T. Cancer statistics, 1991. Bull Assoc Med PR 1991;83 225 42
  • 3
    Byrne RL, Leung H, Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 1996;77 627 33
  • 4
    Leung HY, Weston J, Gullick WJ et al. A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma. Br J Urol 1997;79 212 6
  • 5
    Tsuka H, Mori H, Li B et al. Enhanced hepatocyte growth factor level in human prostate cancer treated with endocrine therapy. Int J Oncol 1998;13 169 76
  • 6
    Woessner RD, Wright PS, Loudy DE et al. Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium. Exp Mol Pathol 1998;65 37 52
  • 7
    Dalal R & Djakiew D. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol 1997;134 15 22
  • 8
    Lewin GR & Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 1996;19 289
  • 9
    Fariñas I & Reichardt LF. Neurotrophic factors and their receptors: implications of genetic studies. Semin Neurosci 1996;8 133 43
  • 10
    Shibayama E & Koizumi H. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 1996;148 1807 18
  • 11
    Yamamoto M, Sobue G, Yamamoto K et al. Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, trkA, trkB, and trkC) in the adult human peripheral nervous system and nonneuronal tissues. Neurochem Res 1996;21 929 38
  • 12
    Pflug BR, Onoda M, Lynch JH. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 1992;52 5403 6
  • 13
    Pflug BR, Dionne C, Kaplan DR et al. Expression of Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995;136 262 8
  • 14
    MacGrogan D, Saint-Andre JP, Dicou E. Expression of nerve growth factor and nerve growth factor receptor genes in human tissues and in prostatic adenocarcinoma cell lines. J Neurochem 1992;59 1381 91
  • 15
    Graham CW, Lynch JH, Djakiew D. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 1992;147 1444 7
  • 16
    Paul A & Habib F. Low-affinity nerve growth factor receptors (p75LNGFR ) in human prostate tissue: stromal localisation. Urol Res 1998;26 111 6
  • 17
    Djakiew D, Pflug BR, Delsite R et al. Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res 1993;53 1416 20
  • 18
    Paul AB, Grant ES, Habib FK. The expression and localization of β-nerve growth factor (β-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation. Br J Cancer 1996;74 1990 6
  • 19
    Katoh-Semba R, Kaisho Y, Shintani A et al. Tissue distribution and immunocytochemical localization of neurotrophin-3 in the brain and peripheral tissues of rats. J Neurochem 1996;66 330 7
  • 20
    Carter BD & Lewin GR. Neurotrophins live or let die: does p75NTR decide? Neuron 1997;18 187 90
  • 21
    Geldof AA, De Kleijn MA, Rao BR et al. Nerve growth factor stimulates in vitro invasive capacity of DU 145 human prostate cancer cells. J Cancer Res Clin Oncol 1997;123 107 12
  • 22
    Delsite R & Djakiew D. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines. J Androl 1996;17 481 90
  • 23
    Guate JL, Escaf S, Menendez CL et al. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. Urol Int 1997;59 149 53
  • 24
    Angelsen A, Sandvik AK, Syversen U et al. NGF-beta, NE-cells and prostatic cancer cell lines. A study of neuroendocrine expression in the human prostatic cancer cell lines DU-145, PC-3, LNCaP, and TSU-pr1 following stimulation of the nerve growth factor-beta. Scand J Urol Nephrol 1998;32 7 13
  • 25
    Chao MV & Hempstead BL. p75 and Trk: a two-receptor system. Trends Neurosci 1995;18 321 6
  • 26
    Terenghi G, Mann D, Kopelman PG et al. trkA and trkC expression is increased in human diabetic skin. Neurosci Lett 1997;228 33 6
  • 27
    Di Marco E, Cutuli N, Guerra L et al. Molecular cloning of trkE, a novel trk-related putative tyrosine kinase receptor isolated from normal human keratinocytes and widely expressed by normal human tissues. J Biol Chem 1993;268 24290 5
  • 28
    Donovan MJ, Miranda RC, Kraemer R et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 1995;147 309 24
  • 29
    Pérez M, Regan T, Pflug B et al. Loss of the low affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 1997;30 274 9
  • 30
    Pflug BRNeurotrophin receptor expression in prostate cancer. PhD Thesis. Department of Cell Biology, Georgetown University Medical Center, Washington DC, USA, 1997
  • 31
    Djakiew D, Delsite R, Pflug BR et al. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res 1991;51 3304 10
  • 32
    Djakiew D. Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J Androl 1992;13 476 87
  • 33
    Dionne CA, Camoratto AM, Jani JP et al. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751. Clin Cancer Res 1998;4 1887 98